{"id":"conventional-ip-antibiotics","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea, vomiting)"},{"rate":null,"effect":"Allergic reactions (rash, urticaria)"},{"rate":null,"effect":"Photosensitivity (with certain classes)"},{"rate":null,"effect":"Ototoxicity (with aminoglycosides)"},{"rate":null,"effect":"Nephrotoxicity (with aminoglycosides)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IP antibiotics refer to a broad category of conventional antimicrobial agents that have been in clinical use for decades. These drugs typically work through well-characterized mechanisms such as inhibition of bacterial ribosomal protein synthesis (e.g., aminoglycosides, tetracyclines, macrolides), disruption of bacterial cell wall synthesis (e.g., beta-lactams), or inhibition of nucleic acid synthesis. The specific mechanism depends on the antibiotic class within this conventional portfolio.","oneSentence":"Conventional IP antibiotics inhibit bacterial protein synthesis or cell wall integrity through established mechanisms, thereby killing or stopping the growth of susceptible bacteria.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:43:53.728Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (broad spectrum depending on specific antibiotic class and susceptibility)"}]},"trialDetails":[{"nctId":"NCT05971537","phase":"PHASE4","title":"Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis","status":"RECRUITING","sponsor":"Alice Ho Miu Ling Nethersole Hospital","startDate":"2023-06-15","conditions":"Peritoneal Dialysis-associated Peritonitis","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"conventional IP antibiotics","genericName":"conventional IP antibiotics","companyName":"Alice Ho Miu Ling Nethersole Hospital","companyId":"alice-ho-miu-ling-nethersole-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conventional IP antibiotics inhibit bacterial protein synthesis or cell wall integrity through established mechanisms, thereby killing or stopping the growth of susceptible bacteria. Used for Bacterial infections (broad spectrum depending on specific antibiotic class and susceptibility).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}